Pioneering Transformative T-Cell Therapies | Lyell
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients. Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.
Our Pipeline - Lyell
Lyell has immense potential to target aggressive malignancies. Our diverse pipeline targets B-cell lymphoma, triple-negative breast cancer, non-small cell lung cancer, ovarian cancer and endometrial cancer — but these initial indications are only the beginning.
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its …
2024年10月24日 · Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response.
Our Team - Lyell
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to effective cell therapy for solid tumors.
Our Science - Lyell
Lyell’s genetic reprogramming technologies are designed to delay T-cell exhaustion and create more potent T cells with enhanced, durable antitumor activity in the immunosuppressive tumor microenvironment. Our technologies target the activator protein 1 (AP-1) transcription factor pathway, which plays a key role in T-cell effector function.
Lyell Immunopharma Receives FDA Orphan Drug Designation for …
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an ...
Our Story - Lyell
Lyell is a clinical-stage cell therapy company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies. We are pioneering novel technology designed to generate T cells that drive long-lasting clinical response.
Lyell has developed LYL119, a ROR1-targeted chimeric antigen receptor (CAR) T-cell product enhanced with four T-cell reprogramming technologies to improve CAR
Publications and Presentations - Lyell
Lyell, Epi-R, Stim-R, LyFE Manufacturing Center and the Lyell logo are trademarks owned by Lyell Immunopharma, Inc. About Us Our Story Our Team. Our Science Our Technology Bibliography Lyell Publications & Presentations. Our Pipeline. Our Cell Therapies Cell Therapy Our Product Candidates.
* Authors contributed equally. 1) Lyell Immunopharma, Inc., South San Francisco, CA and Seattle, WA. 2) Fred Hutch Cancer Center, Seattle, WA. 3) Sarah Cannon Research Institute, Nashville, TN. For more information, please contact: [email protected] Background • Chimeric antigen receptor (CAR) T-cell therapy is effective in treating